CGEN Overview

Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Wall Street analysts forecast CGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGEN is4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Compugen Ltd revenue for the last quarter amounts to 67.33M USD, increased 4477.29

Compugen Ltd. EPS for the last quarter amounts to USD, decreased -100.00

Compugen Ltd (CGEN) has 53 emplpoyees as of March 12 2026.

Today CGEN has the market capitalization of 215.58M USD.